Bc von willebrand reagent

Manufactured by Siemens

Sourced in Germany, France

The BC von Willebrand Reagent is a laboratory product designed for the quantitative determination of von Willebrand factor (vWF) antigen in human plasma. It is intended for use in clinical laboratories as an aid in the diagnosis and monitoring of von Willebrand disease.

Automatically generated - may contain errors

Lab products found in correlation

Actin fs, by Siemens (1 mentions) Innovance, by Siemens (1 mentions) Zymutest t pa antigen, by Hyphen Biomed (1 mentions) Innovance antithrombin, by Siemens (1 mentions) Bcs xp analyzer, by Siemens (1 mentions) Innovance d dimer, by Siemens (1 mentions) Multifibren u, by Siemens (1 mentions)

4 protocols using bc von willebrand reagent

Comprehensive Characterization of von Willebrand Factor in Plasma Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

It was carried out as indicated in our previous publication [18 (link)]. Basically FVIII:C, VWF:Ag, VWF:RCo and VWF:CB were measured in all recruited individuals’ plasma samples. FVIII:C was assessed by a one-stage clotting assay using Actin FS as activator on a Behring Coagulation Timer (BCT) (Siemens Healthcare Diagnostics). The VWF:Ag was measured using the ELISA kit, DG–EIA VWF (Diagnostic Grifols). VWF:CB with collagen type III was determined by the ELISA kit DG–CBA VWF (Diagnostic Grifols), on a Triturus Immunoassay System. In some samples VWF:CB was assayed by using type VI collagen (TECHNOZYMR VWF:CBA ELISA Collagen Type VI, Technoclone). The VWF:RCo test was performed on a BCT using the BC von Willebrand Reagent (Siemens Healthcare Diagnostics), and also by using conventional light transmission aggregometry. Throughout literature, abnormal VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag has been defined between 0.5–0.7 to distinguish between VWD type 1 and type 2 [12 (link)]. In our study, we considered a ratio cut off 0.7 as indicative of a qualitative VWF defect.
The VWF:FVIIIB was assessed using an in-house ELISA [20 (link)] in all patients who presented with a FVIII:C/VWF:Ag ratio <1, and in those in whom a type 2N mutation was found.
Lyophilized, reconstituted normal control plasma calibrated to the World Health Organization standard was used as reference.

Pérez-Rodríguez A., Batlle J., Corrales I., Borràs N., Rodríguez-Trillo Á., Lourés E., Cid A.R., Bonanad S., Cabrera N., Moret A., Parra R., Mingot-Castellano M.E., Navarro N., Altisent C., Pérez-Montes R., Marcellini S., Moreto A., Herrero S., Soto I., Fernández Mosteirín N., Jiménez-Yuste V., Alonso N., de Andrés Jacob A., Fontanes E., Campos R., Paloma M.J., Bermejo N., Berrueco R., Mateo J., Arribalzaga K., Marco P., Palomo Á., Castro Quismondo N., Iñigo B., Nieto M.D., Vidal R., Martínez M.P., Aguinaco R., Tenorio M., Ferreiro M., García-Frade J., Rodríguez-Huerta A.M., Cuesta J., Rodríguez-González R., García-Candel F., Dobón M., Aguilar C., Batlle F., Vidal F, & López-Fernández M.F. (2018). Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE, 13(6), e0197876.

+ Open protocol

+ Expand

VWF Binding Activity Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

VWF:RCo (BC von Willebrand reagent [Siemens]) and VWF glycoprotein Ib (GpIb) binding activity (Innovance, Siemens) were determined by commercially available assays as described previously.23, 24

Zhu S., Gilbert J.C., Hatala P., Harvey W., Liang Z., Gao S., Kang D, & Jilma B. (2020). The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer. Journal of Thrombosis and Haemostasis, 18(5), 1113-1123.

+ Open protocol

+ Expand

von Willebrand Factor Activity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Citrated plasma was diluted sevenfold in imidazole buffer (100 mM imidazole, 100 mM NaCl, pH 7.4). A standard dilution curve was prepared of diluted normal pooled plasma. Then, 200 µl BC von Willebrand Reagent (Siemens Healthcare, Erlangen, Germany) was added to the 70 µl sample in a 96-well clear Maxisorp microtiter plate. Following 10 min incubation at 37°C and 20 min incubation at room temperature, to allow platelet aggregates to precipitate, 100 µl of the mixture was transferred to a new plate and non-aggregated platelets were measured at 350 nm. Ristocetin co-factor activity (VWF:RCo) was calculated with a five-parametric curve-fitting method, using a dilution curve of the standard. The lower detection limit of the assay was 3% VWF:RCo.

Mebius M.M., Adegnika A.A., Zinsou J.F., Agobe J.C.D., Honkpehedji Y.J., Yazdanbakhsh M., van Dam G.J., Corstjens P.L.A.M., Tielens A.G.M., de Groot P.G., Urbanus R.T, & van Hellemond J.J. (2019). Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren. Journal of helminthology, 94.

+ Open protocol

+ Expand

Preoperative Biomarkers for Postoperative Myocardial Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols

The markers were as follows: antithrombin (chromogenic method;
Innovance Antithrombin; Siemens, Marburg, Germany), activity of factor VIII (one-stage clotting assay; Siemens), concentration of von Willebrand factor (vWF:Ag; ELISA method; Zymutest vWF; Hyphen BioMed, Andresy, France), vWF activity (vWF:CoR; turbidimetric method; BC von Willebrand Reagent; Siemens), fibrinogen (Clauss method; Multifibren U; BCS XP analyzer; Siemens), D-dimer (turbidimetric method; Innovance D-Dimer; Siemens), plasmin-antiplasmin (PAP) complexes (ELISA method; Technozym PAP Complex;
Editor's key points
• Myocardial injury after non-cardiac surgery (MINS), as defined by troponin elevation within 30 days of surgery, correlates with poorer prognosis.
• In a retrospective subanalysis of vascular surgery patients from the VISION study, patients with MINS had preoperative elevation of biomarkers for hypercoagulability and inflammation.
• Preoperative hypercoagulability and inflammation predict MINS, which provides a potential target for preoperative risk reduction.
Technoclone, Vienna, Austria), and tissue plasminogen activator (ELISA method; Zymutest t-PA Antigen, Hyphen BioMed).

Górka J., Polok K., Iwaniec T., Górka K., Wludarczyk A., Fronczek J., Devereaux P.J., Eikelboom J.W., Musial J, & Szczeklik W. (2017). Altered preoperative coagulation and fibrinolysis are associated with myocardial injury after non-cardiac surgery. British journal of anaesthesia, 118(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!